Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU-Reference-Cited by-同舟云学术

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

Published:2021-11-02 Issue:12 Volume:41 Page:1099-1107
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Shirley Matt

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01093-8.pdf

Reference21 articles.

1. European Medicines Agency. Remicade (infliximab): summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf. Accessed 04 Oct 2021.

2. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28(3):313–21.

3. Blair HA, Deeks ED. Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs. 2016;30(5):469–80.

4. Lamb YN, Scott LJ, Deeks ED. SB2: an infliximab biosimilar. BioDrugs. 2017;31(5):461–4.

5. Al-Salama ZT. PF-06438179/GP1111: an infliximab biosimilar. BioDrugs. 2018;32(6):639–42.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic arthritis: A case report and pharmacokinetic considerations;Int. Journal of Clinical Pharmacology and Therapeutics;2024-03-01

2. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses;Scandinavian Journal of Gastroenterology;2023-11-25

3. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis;Therapeutic Advances in Gastroenterology;2023-01

4. Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial;Rheumatology;2022-12-19

5. Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within 14‐day treatment cycle in Crohn’s disease;Alimentary Pharmacology & Therapeutics;2022-02-28